Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Willem Alffenaar

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
British Journal of Clinical Pharmacology|July 27, 2018
The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysisMin Zhang, Shuqiang Wang, Bob Wilffert, et al.
British Journal of Clinical Pharmacology|January 19, 2021
Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort studyYazhou Gao, Lina Davies Forsman, Weihua Ren, et al.
Frontiers in Pharmacology|June 30, 2020
Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic ReviewHannah Yejin Kim, Anne-Grete Märtson, Erwin Dreesen, et al.
Therapeutic Drug Monitoring|October 15, 2021
Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyHannah Yejin Kim, Sara Baldelli, Anne-Grete Märtson, et al.
Critical Care Medicine|May 3, 2021
Predictive Performance of Bayesian Vancomycin Monitoring in the Critically IllSujita W Narayan, Yann Thoma, Philip G Drennan, et al.
Internal Medicine Journal|February 22, 2022
Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitalsAngela Pearce, Bronwyn Terrill, Jan-Willem Alffenaar, et al.
Clinical Pharmacokinetics|February 28, 2024
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in NeonatesDua'a Alrahahleh, Yann Thoma, Ruth Van Daele, et al.
Scientific Reports|August 28, 2024
Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infectionSandor-Adrian Klis, Ymkje Stienstra, Kabiru M Abass, et al.
Frontiers in Pharmacology|October 27, 2022
Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional surveyJingjing Hou, Debbie Marriott, Dario Cattaneo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 6, 2025
Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosisDiana H Quan, Trixie Wang, Elena Martinez, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
British Journal of Clinical Pharmacology|July 27, 2018
The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysisMin Zhang, Shuqiang Wang, Bob Wilffert, et al.
British Journal of Clinical Pharmacology|January 19, 2021
Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort studyYazhou Gao, Lina Davies Forsman, Weihua Ren, et al.
Frontiers in Pharmacology|June 30, 2020
Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic ReviewHannah Yejin Kim, Anne-Grete Märtson, Erwin Dreesen, et al.
Therapeutic Drug Monitoring|October 15, 2021
Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyHannah Yejin Kim, Sara Baldelli, Anne-Grete Märtson, et al.
Critical Care Medicine|May 3, 2021
Predictive Performance of Bayesian Vancomycin Monitoring in the Critically IllSujita W Narayan, Yann Thoma, Philip G Drennan, et al.
Internal Medicine Journal|February 22, 2022
Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitalsAngela Pearce, Bronwyn Terrill, Jan-Willem Alffenaar, et al.
Clinical Pharmacokinetics|February 28, 2024
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in NeonatesDua'a Alrahahleh, Yann Thoma, Ruth Van Daele, et al.
Scientific Reports|August 28, 2024
Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infectionSandor-Adrian Klis, Ymkje Stienstra, Kabiru M Abass, et al.
Frontiers in Pharmacology|October 27, 2022
Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional surveyJingjing Hou, Debbie Marriott, Dario Cattaneo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 6, 2025
Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosisDiana H Quan, Trixie Wang, Elena Martinez, et al.
Pageof 10